Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems

  title={Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems},
  author={Yeon Hong Lee and Kyung Hee Kim and In Kyung Yoon and Kyung Eun Lee and Inkoo Chun and Jeong Yeon Rhie and Hye sun Gwak},
  journal={European Journal of Drug Metabolism and Pharmacokinetics},
  • Y. Lee, K. Kim, H. Gwak
  • Published 1 December 2014
  • Biology, Chemistry, Medicine
  • European Journal of Drug Metabolism and Pharmacokinetics
The objective of this study was to investigate the pharmacokinetic characteristics of levodopa (l-dopa) from nasal powder formulations using highly water-soluble levodopa methyl ester hydrochloride (LDME). In vivo pharmacokinetic studies were carried out with formulated LDME nasal powders. After oral and intravenous administration of l-dopa and carbidopa and intranasal administration LDME to the rat, l-dopa concentrations were determined in plasma and the brain using high-performance liquid… 
Design and Development of Levodopa Loaded Polymeric Nanoparticles for Intranasal Delivery
This work illustrates that formulating L-Dopa into chitosan nanoparticles for intranasal delivery is a potentially viable formulation strategy to improve the bioavailability of the drug for the treatment of Parkinson’s disease.
Rapid High-Performance Liquid Chromatography Method for Levodopa Quantitation at Low UV Wavelength: Application of Pharmacokinetics Study in Rat Following Intranasal Delivery.
Pharmacokinetic parameters including bioavailability of 75 and 85% with mean residence time of 78 and 94 min were estimated using the validated HPLC method, which indicated that levodopa nasal gel may be a good alternative with appropriate pharmacokinetic outcome.
Opportunity and challenges of nasal powders: Drug formulation and delivery
Systemic Delivery of Peptide Hormones Using Nasal Powders: Strategies and Future Perspectives
Nasal powders are a promising drug delivery system that may be safer and more effective than traditional injections and presently marketed nasal liquids for peptide hormone drugs.
Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: Role of docosahexaenoic acid.
Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease
LD ester prodrugs have demonstrated an adequate intranasal delivery of LD, thus enabling the absorption of therapeutic agents to the brain, and the future of utilizing pro drugs for the treatment of PD seems to be bright.
Spray dried powders for nasal delivery: Process and formulation considerations.
Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease
These findings favour the concept of chronic levodopa/DDI application with concomitant inhibition of COMT and monoamine oxidase, since deamination of dopamine via this enzyme also generates free radicals.


Design and evaluation of levodopa methyl ester intranasal delivery systems.
The results suggested that LDME nasal powder formulations could be useful delivery systems of L-dopa, and were suggested to be relatively stable in acidic solutions.
Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems.
Enhancement of the Systemic and CNS Specific Delivery of L-Dopa by the Nasal Administration of Its Water Soluble Prodrugs
Utilization of water soluble prodrugs of L-dopa via the nasal route in the treatment of Parkinson's disease may have therapeutic advantages such as improved bioavailability, decreased sideeffects, and potentially enhanced CNS delivery.
Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent.
Pharmacokinetics of levodopa
These attempts have proved so far only partly successful, due to the complex alterations in cerebral levodopa kinetics which accompany the progressive degeneration of the nigrostriatal dopaminergic system in PD patients.
Mucosal drug delivery using cellulose derivatives as a functional polymer.
  • Y. Suzuki, Y. Makino
  • Biology
    Journal of controlled release : official journal of the Controlled Release Society
  • 1999
Impact of Gastric Emptying on Levodopa Pharmacokinetics in Parkinson Disease Patients
Fine tuning of LD application, which considers gastric emptying, becomes more and more essential in advanced PD stages with a reduced striatal neuronal dopamine capacity, which is responsible for maintenance of motor response in early PD patients.
The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson's disease.
A Pharmacokinetic Model to Predict the PK Interaction of L-Dopa and Benserazide in Rats
This study is the first investigation where the kinetics of benserazide and Ro 04-5127 have been described by a compartmental model and supports the hypothesis that Ro 04/5127 is the primary active metabolite of bensonazide.
Nasal absorption of propranolol from different dosage forms by rats and dogs.
The blood levels of propranolol in rats and dogs were compared after the administration of nasal, intravenous, and oral solutions, and the bioavailability of the sustained-release formulation was identical to that of the intravenous administration.